Prestige Consumer Healthcare (PBH) reported $281.62 million in revenue for the quarter ended March 2026, representing a year-over-year decline of 5%. EPS of $1.23 for the same period compares to $1.32 a year ago.
The reported revenue represents a surprise of -4.29% over the Zacks Consensus Estimate of $294.24 million. With the consensus EPS estimate being $1.39, the EPS surprise was -11.72%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Prestige Consumer Healthcare performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- OTC Healthcare- International: $47.07 million compared to the $47.65 million average estimate based on three analysts. The reported number represents a change of -1% year over year. Revenues- OTC Healthcare- North American: $234.55 million versus $245.83 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -5.8% change. Gross profit- OTC Healthcare- North American: $121.37 million versus $142.35 million estimated by two analysts on average. Gross profit- OTC Healthcare- International: $24.93 million versus the two-analyst average estimate of $27.92 million.View all Key Company Metrics for Prestige Consumer Healthcare here>>>
Shares of Prestige Consumer Healthcare have returned -11% over the past month versus the Zacks S&P 500 composite's +8.6% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Prestige Consumer Healthcare Inc. (PBH): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).